As regards to this, future high-quality intervention studies are required to evaluate whether improvement or resolution of NAFLD achieved by treatment with GLP-1RAs and SGLT-2 inhibitors (alone or in combination) may also reduce the long-term risk of new-onset HF. Here, SLC5A2 is linked to metabolic dysfunction-associated steatotic liver disease.